Year: 2025
Type: article
Abstract: Hypertension remains a global health challenge, contributing significantly to cardiovascular morbidity and mortality. Despite the availability of various antihypertensive drugs, many patients fail to achieve optimal blood pressure control due to factors such as medication resistance, side effects, and patient non-adherence [1]. Recent research has led to groundbreaking advancements in hypertension treatment, including novel pharmacological therapies, gene-targeted interventions, and innovative non-pharmacological approaches. New classes of drugs, such as angiotensin receptor neprilysin inhibitors (ARNIs) and endothelin receptor antagonists, have demonstrated superior efficacy in blood pressure reduction compared to traditional therapies [2]. Additionally, gene-editing technologies like CRISPR-Cas9 are being explored for their potential to modulate genes associated with hypertension [3]. Non-pharmacological innovations, such as renal denervation therapy and bioelectronic medicine, offer alternative strategies for treatment-resistant hypertension [4]. Moreover, artificial intelligence (AI) and machine learning are transforming hypertension management by enabling personalized treatment plans based on predictive analytics [5]. This article reviews these emerging therapies, their clinical implications, and the barriers that need to be overcome for widespread adoption. The integration of these new treatment modalities has the potential to revolutionize hypertension management and improve patient outcomes worldwide.
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408955750